PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
163 hedge funds and large institutions have $297M invested in PDL BioPharma, Inc. in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 36 increasing their positions, 56 reducing their positions, and 32 closing their positions.
7% less funds holding
Funds holding: 176 → 163 (-13)
25% less capital invested
Capital invested by funds: $394M → $297M (-$96.8M)
34% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 32
36% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 56
44% less call options, than puts
Call options by funds: $107K | Put options by funds: $190K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.44M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$4.91M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.78M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$2.48M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$13.8M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$2.96M |
| 3 |
Man Group
London,
United Kingdom
|
-$2.71M |
| 4 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
-$2.56M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.09M |
PDLI Hedge Fund Activity: Q2 2018 in Review
163 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2018, worth a combined $297M — down 25% from $394M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of PDLI and 21 opened new positions — a net loss of 11 holders — while 56 trimmed existing stakes and 36 added.
The largest buyer was Citadel Advisors, adding an estimated $5.44M. The largest seller was Mackenzie Financial, cutting an estimated $13.8M.
- 163 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2018, down from 176 in Q1 2018.
- Funds reported $297M of PDL BioPharma, Inc. stock for Q2 2018, down 25% quarter-over-quarter.
- 21 funds opened new PDL BioPharma, Inc. positions in Q2 2018 and 32 closed out, a net change of -11 holders.
- The largest PDL BioPharma, Inc. buyer in Q2 2018 was Citadel Advisors, an estimated $5.44M added.
- The largest PDL BioPharma, Inc. seller in Q2 2018 was Mackenzie Financial, an estimated $13.8M sold.
Based on aggregated 13F filings for Q2 2018.